S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q4 2024

Baker Bros Advisors

Period: Q4 2024 Β· Filed: 2025-02-14
View on SEC EDGAR β†—
AUM
$9.36B
Total portfolio value
Positions
95
Reported securities
Top Holding
INCY
22.7% $2.12B
QoQ Changes
+8 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2025-02-14) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
INCYIncyte Corporation$2.12B22.68%$69.07$116.86+69.2%
22.7%
ONCBeiGene, Ltd.$1.76B18.81%$184.71$297.65+61.1%
18.8%
ACADACADIA Pharmaceuticals Inc.$786.8M8.40%$18.35$25.97+41.5%
8.4%
MDGLMadrigal Pharmaceuticals, Inc.$609.3M6.51%$308.57$528.10+71.1%
6.5%
SMMTSummit Therapeutics Inc.$435.9M4.66%$17.84$15.42-13.6%
4.7%
RVMDRevolution Medicines, Inc.$347.2M3.71%$43.74$189.24+332.6%
3.7%
INSMInsmed Incorporated$345.7M3.69%$69.04$111.60+61.6%
3.7%
RYTMRhythm Pharmaceuticals, Inc.$340.6M3.64%$55.98$114.17+104.0%
3.6%
KYMRKymera Therapeutics, Inc.$241.2M2.58%$40.23$113.51+182.2%
2.6%
KODKodiak Sciences Inc.$172.2M1.84%$9.95$38.54+287.3%
1.8%
EWTXEdgewise Therapeutics, Inc.$164.4M1.76%$26.70$39.56+48.2%
1.8%
BCYCBicycle Therapeutics plc$152.4M1.63%$14.00$4.35-68.9%
1.6%
REPLReplimune Group, Inc.$133.8M1.43%$12.11$11.58-4.4%
1.4%
ALKSAlkermes plc$120.3M1.28%$28.76$54.58+89.8%
1.3%
Insmed Incorporated$92.9M0.99%β€”β€”
1.0%
TRDAEntrada Therapeutics, Inc.$84.1M0.90%$17.29$7.72-55.4%
0.9%
ABCLAbCellera Biologics Inc.$80.7M0.86%$2.93$8.11+176.8%
0.9%
DNLIDenali Therapeutics Inc.$76.0M0.81%$20.38$25.83+26.7%
0.8%
NRIXNurix Therapeutics, Inc.$73.1M0.78%$18.84$23.97+27.2%
0.8%
ARGXargenx SE$68.8M0.74%$615.00$939.68+52.8%
0.7%
RAREUltragenyx Pharmaceutical Inc.$66.3M0.71%$42.07$33.47-20.4%
0.7%
KNSAKiniksa Pharmaceuticals International, plc$55.8M0.60%$19.78$64.53+226.2%
0.6%
IMTXImmatics N.V.$51.7M0.55%$7.11$9.95+39.9%
0.6%
CRSPCRISPR Therapeutics AG$51.5M0.55%$39.36$60.08+52.6%
0.6%
STOKStoke Therapeutics, Inc.$51.1M0.55%$11.03$32.70+196.5%
0.6%
IMCRImmunocore Holdings plc$44.7M0.48%$29.50$32.50+10.2%
0.5%
ROIVRoivant Sciences Ltd.$44.6M0.48%$11.83$35.13+197.0%
0.5%
SERASera Prognostics, Inc.$44.2M0.47%$8.14$2.00-75.4%
0.5%
IMVTImmunovant, Inc.$42.3M0.45%$24.77$38.79+56.6%
0.5%
XENEXenon Pharmaceuticals Inc.$39.0M0.42%$39.20$60.96+55.5%
0.4%

Quarter-on-Quarter Activity

Q4 2024 vs. Q3 2024

New Positions (8)

TickerIssuerNotional
Ionis Pharmaceuticals, Inc.$29.5M
GRALGRAIL, Inc.$29.1M
CADLCandel Therapeutics, Inc.$25.9M
VIRVir Biotechnology, Inc.$8.0M
NTLAIntellia Therapeutics, Inc.$7.5M
BNTXBioNTech SE$5.1M
IRONDisc Medicine, Inc.$4.9M
DBVTDBV Technologies S.A.$4.5M

Exited Positions (8)

TickerIssuerNotional
TNGXTango Therapeutics, Inc.$5.8M
CRNXCrinetics Pharmaceuticals, Inc.$5.3M
DBVTDBV Technologies S.A.$5.1M
ALECAlector, Inc.$4.3M
NAMSNewAmsterdam Pharma Company N.V.$1.6M
AVTEAerovate Therapeutics, Inc.$1.3M
PFEPfizer Inc.$1.0M
BCRXBioCryst Pharmaceuticals, Inc.$0.6M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
GPCRStructure Therapeutics Inc.$6.0M+322.9%
IONSIonis Pharmaceuticals, Inc.$3.6M+60.2%
CRSPCRISPR Therapeutics AG$11.9M+55.1%+52.6%
MRUSMerus N.V.$3.9M+50.0%
NGNENeurogene Inc.$-3.7M+47.9%
CELCCelcuity Inc.$7.1M+42.9%
IMVTImmunovant, Inc.$7.4M+39.4%+56.6%
KALAKALA BIO, Inc.$3.3M+34.8%

Trimmed (4)

TickerIssuerNotionalShares Ξ”Since Filing
BMEABiomea Fusion, Inc.$-15.7M-31.2%
SGMTSagimet Biosciences Inc.$0.5M-31.0%
ONCBeiGene, Ltd.$-612.2M-9.8%+61.1%
RYTMRhythm Pharmaceuticals, Inc.$5.4M-4.9%+104.0%
← Back to Hedge Funds